CJC-1295 — Wolverine Health

How it works

A synthetic GHRH analog that stimulates GH release via the GHRH receptor. The DAC-modified version binds plasma albumin, extending the half-life from minutes to days. A Phase II human trial in healthy adults showed sustained GH and IGF-1 elevation over weeks. What it does in terms of body composition or performance in non-deficient adults — that part hasn't been tested rigorously.

FDA status: No FDA approval. Not on the PCAC July 2026 review docket.
WADA status: Permitted in sport
Route: subcutaneous injection

Key studies

CJC-1295 stimulates GH and IGF-1 secretion in healthy adults — Teichman et al. (2006)

CJC-1295 with DAC produced sustained elevation of GH and IGF-1 in healthy adults across multiple dose levels in a Phase II trial, with a half-life of 6–8 days.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on CJC-1295

Peptide access by US state: why the regulatory patchwork right now is real

The federal compounding framework applies the same way in every state. The state pharmacy boards do not. The result is a real state-by-state patchwork that decides whether a telehealth prescription for a compounded peptide is actually fillable where you live.

What RFK Jr.'s February 2026 announcement actually said about peptides

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

Growth hormone secretagogues: what they are and why four peptides keep showing up together

WADA

CJC-1295, ipamorelin, sermorelin, and tesamorelin all sit in the growth-hormone-secretagogue class. They are routinely confused for each other. Here is the mechanism, the human evidence on each, and the four separate regulatory files behind the shared label.

CJC-1295 vs ipamorelin: which half of the GHRH stack has the deeper evidence file?

WADA

CJC-1295 and ipamorelin get sold side-by-side as the growth-hormone protocol — one lifts the baseline, the other adds the pulse. Two molecules, two different mechanisms, two human evidence files that almost don't overlap. Here is what the published data actually separates them on.

CJC-1295 and growth hormone: a measured look at the evidence

WADA

CJC-1295 is the long-acting GHRH analog the muscle-and-aging marketing keeps pointing at. Here's what's actually known, what the DAC-versus-no-DAC question hides, and why one well-run Phase 1 trial in 2006 is still doing all the work.

CJC-1295: GHRH Analog Research Overview and Regulatory Context

WADA

Science-journalism overview of CJC-1295, a synthetic GHRH analog studied for sustained growth hormone release — what animal and limited human data show, and its regulatory status in 2026.